APOE and Alzheimer disease: In the testing set, after adjusting for APOE genotypes and the clinical factors in the CogDrisk‐AD risk model, the AD protein risk score was significantly positively associated with the risk of new‐onset AD (per SD increment: HR, 2.30; 95% CI, 1.95, 2.71) (Figure 1a).